Transgene Announces Financial Calendar for 2019

STRASBOURG, France--(BUSINESS WIRE)--

Regulatory News:

Transgene (Paris: TNG) today announced its financial reporting dates for 2019:

About Transgene
Transgene (Euronext: TNG) is a publicly traded French biotechnology company focused on designing and developing targeted immunotherapies for the treatment of cancer and infectious diseases. Transgene’s programs utilize viral vector technology with the goal of indirectly or directly killing infected or cancerous cells. The Company’s lead clinical-stage programs are: TG4010, a therapeutic vaccine against non-small cell lung cancer, Pexa-Vec, an oncolytic virus against liver cancer, and TG4001, a therapeutic vaccine against HPV-positive head and neck cancers. The Company has several other programs in clinical development, including TG1050 (a therapeutic vaccine for the treatment of chronic hepatitis B) and TG6002 (an oncolytic virus for the treatment of solid tumors).
With its proprietary Invir.IO™, Transgene builds on its expertise in viral vectors engineering to design a new generation of multifunctional oncolytic viruses.
myvac™, an individualized MVA-based immunotherapy platform designed to integrate neoantigens, completes this innovative research portfolio.
Additional information about Transgene is available at www.transgene.fr.
Follow us on Twitter: @TransgeneSA

View source version on businesswire.com: https://www.businesswire.com/news/home/20181217005522/en/

Transgene:
Jean-Philippe Del/Lucie Larguier
+33 (0)3 88 27 11 21
[email protected]

Media contacts:
Citigate Dewe Rogerson
David Dible/Marine Perrier/Sylvie Berrebi
+44 (0)20 7638 9571
[email protected]

Source: Transgene

You May Also Be Interested In

• Dollar Tree upgraded on earnings upside potential despite ongoing traffic woes
• Goldman Sachs Reinstates Erste Group Bank (EBS:AV) (EBKDY) at Buy
• BMO Capital bullish on top pick Royal Caribbean as cruise tailwinds ’favorable’